Below are the financial statements of BridgeBio Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in thousands of USD | 2024 as of 2024-12-31 | 2023 as of 2023-12-31 |
|---|---|---|
| Assets | — | — |
| Current assets | — | — |
| Cash and cash equivalents | 681,101a | 375,935a |
| Investments in equity securities | 0a | 58,949a |
| Accounts receivable | 4,722a | 1,751a |
| Restricted cash | 126a | 16,653a |
| Prepaid expenses and other current assets | 34,743a | 24,305a |
| Total current assets | 720,692a | 477,593a |
| Investment in nonconsolidated entities | 143,747a | 0a |
| Property and equipment, net | 7,011a | 11,816a |
| Operating lease right-of-use assets | 5,767a | 8,027a |
| Intangible assets, net | 23,926a | 26,319a |
| Other assets | 18,195a | 22,625a |
| Total assets | 919,338a | 546,380a |
| Liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | — | — |
| Current liabilities | — | — |
| Accounts payable | 9,618a | 10,655a |
| Accrued compensation and benefits | 58,329a | 57,370a |
| Accrued research and development liabilities | 34,272a | 29,765a |
| Operating lease liabilities, current portion | 4,506a | 4,128a |
| Deferred revenue, current portion | 14,604a | 6,096a |
| Accrued professional and other accrued liabilities | 33,071a | 35,830a |
| Total current liabilities | 154,400a | 143,844a |
| 2029 notes, net | 738,872a | 736,905a |
| 2027 notes, net | 545,173a | 543,379a |
| Term loan, net | 437,337a | 446,445a |
| Deferred royalty obligation, net | 479,091a | 0a |
| Operating lease liabilities, net of current portion | 4,696a | 8,981a |
| Deferred revenue, net of current portion | 17,095a | 3,727a |
| Other long-term liabilities | 286a | 5,634a |
| Total liabilities | 2,376,950a | 1,888,915a |
| Redeemable convertible noncontrolling interests | 142a | 478a |
| Stockholders’ deficit | — | — |
| Undesignated preferred stock | 0a | 0a |
| Common stock | 196a | 181a |
| Treasury stock, at cost | -275,000a | -275,000a |
| Additional paid-in capital | 1,903,155a | 1,481,032a |
| Accumulated other comprehensive income | 8a | 31a |
| Accumulated deficit | -3,096,263a | -2,560,501a |
| Total BridgeBio stockholders’ deficit | -1,467,904a | -1,354,257a |
| Noncontrolling interests | 10,150a | 11,244a |
| Total stockholders’ deficit | -1,457,754a | -1,343,013a |
| Total liabilities, redeemable convertible noncontrolling interests and stockholders’ deficit | 919,338a | 546,380a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.